Return on Invested Capital (ROIC): 16.61%
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of 16.61% is 60% above its 5-year average of 10.40%, near the high end of its 5-year range (5.32%–16.61%).
As of Sunday, June 28, 2026. 32.25% above its 12-month average of 12.56%.
GSK Return on Invested Capital (ROIC) Chart
Annual fiscal-year return on invested capital; no daily interpolation.
GSK Average Return on Invested Capital (ROIC) Chart
GSK Current vs Average Return on Invested Capital (ROIC) Chart
GSK Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
16.61%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
12.56%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
12.53%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
10.40%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
10.13%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
11.57%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
14.07%
CURRENT VS TTM AVG
+32.25%
CURRENT VS 3Y AVG
+32.59%
CURRENT VS 5Y AVG
+59.74%
CURRENT VS 10Y AVG
+63.92%
CURRENT VS 15Y AVG
+43.61%
CURRENT VS 20Y AVG
+18.06%
GSK Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GSK plc (GSK) | $105.20B | 16.61% | 12.56% | 12.53% | 10.40% |
| Medtronic plc (MDT)vs › | $103.66B | 6.13% | 6.11% | 5.46% | 5.53% |
| Bristol-Myers Squibb Company (BMY)vs › | $117.46B | 13.90% | 13.75% | 11.92% | 10.17% |
| McKesson Corporation (MCK)vs › | $89.39B | 31.48% | 27.39% | 24.73% | 20.68% |
| HCA Healthcare, Inc. (HCA)vs › | $86.89B | 18.53% | 17.61% | 17.07% | 16.89% |
| Elevance Health Inc. (ELV)vs › | $85.82B | 6.65% | 6.70% | 7.11% | 7.33% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $124.70B | 18.12% | 10.38% | 14.75% | 17.51% |
| Stryker Corporation (SYK)vs › | $127.39B | 8.53% | 10.14% | 10.34% | 10.08% |
| CVS Health Corp. (CVS)vs › | $133.13B | 4.72% | 4.17% | 4.46% | 4.93% |
| Cigna Corporation (CI)vs › | $74.81B | 7.35% | 7.02% | 7.07% | 6.50% |
Capital Efficiency
ROIC
16.6%
ROE
25.2%
Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for GSK plc (GSK)?
- The return on invested capital (ROIC) for GSK stock is 16.61%.
- Is GSK plc's return on invested capital (ROIC) high or low?
- The return on invested capital (ROIC) of 16.61% is 60% above its 5-year average of 10.40%, near the high end of its 5-year range (5.32%–16.61%).
- What is the TTM average return on invested capital (ROIC) for GSK plc (GSK)?
- The TTM average return on invested capital (ROIC) for GSK stock is 12.56%.
- What is the 3Y average return on invested capital (ROIC) for GSK plc (GSK)?
- The 3Y average return on invested capital (ROIC) for GSK stock is 12.53%.
- What is the 5Y average return on invested capital (ROIC) for GSK plc (GSK)?
- The 5Y average return on invested capital (ROIC) for GSK stock is 10.40%.
- What is the 10Y average return on invested capital (ROIC) for GSK plc (GSK)?
- The 10Y average return on invested capital (ROIC) for GSK stock is 10.13%.
- What is the 15Y average return on invested capital (ROIC) for GSK plc (GSK)?
- The 15Y average return on invested capital (ROIC) for GSK stock is 11.57%.
- What is the 20Y average return on invested capital (ROIC) for GSK plc (GSK)?
- The 20Y average return on invested capital (ROIC) for GSK stock is 14.07%.
GSK Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 16.61% |
| 2024-12-31 | 8.51% |
| 2023-12-31 | 11.37% |
| 2022-12-31 | 13.62% |
| 2021-12-31 | 5.32% |
| 2020-12-31 | 6.96% |
| 2019-12-31 | 7.11% |
| 2018-12-31 | 11.17% |
| 2017-12-31 | 7.71% |
| 2016-12-31 | 3.22% |
| 2015-12-31 | 19.86% |
| 2014-12-31 | 11.32% |
| 2013-12-31 | 19.07% |
| 2012-12-31 | 16.50% |
| 2011-12-31 | 19.24% |
| 2010-12-31 | 7.47% |
| 2009-12-31 | 18.79% |
| 2008-12-31 | 16.66% |
| 2007-12-31 | 23.46% |
| 2006-12-31 | 26.65% |
| 2005-12-31 | 24.83% |
| 2004-12-31 | 23.05% |
| 2003-12-31 | 27.54% |
| 2002-12-31 | 27.06% |
| 2001-12-31 | 30.38% |
| 2000-12-31 | 22.71% |
| 1999-12-31 | 25.15% |
| 1998-12-31 | 28.60% |
| 1997-12-31 | 34.22% |
| 1996-12-31 | 37.61% |
Related Metrics
About GSK plc
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Luke Victor Miels